Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi

Citi analyst Samantha Semenkow raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $142 from $131 and keeps a Buy rating on the shares after the FDA approved Imcivree for patients with acquired hypothalamic obesity. The approval positions Rhythm for its next phase of growth, the analyst tells investors in a research note.